New pill takes on tough blood cancers in early trial
NCT ID NCT06846606
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an oral drug called AUTX-703 in 34 adults with relapsed or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal is to check safety and find the right dose. It's an open-label trial, meaning everyone knows they're getting the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AUTX-703 (oral drug)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat blood cancers like AML and MDS.
What could go wrong
This is a very early Phase 1 trial with only 34 participants, so it's mainly checking safety and dosing. It may not show strong anti-cancer effects, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Ohio State University, The James Comprehensive Cancer
Columbus, Ohio, 43210, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Sarah Cannon Center for Blood Cancer at TriStar Centennia
Nashville, Tennessee, 37203, United States
-
UPENN Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States